1Jemal A, Thomas A, Murray T, et al. Cancer statistics, 2002[J]. CA Cancer J Clin, 2002, 52(1): 23-47.
2Saltz LB, Cox JV, Blanke C, et al. Irinotecan plus fluoro- uracil and leucovorin for metastatic colorectal cancer. Iri- notecan Study Group[J]. N Engl J Med, 2000, 343(13): 905-914.
3Sargent D J, Niedzwiechi D, O' Cormell MJ, et al. Rec- ommendation for caution with irinotecan, fluorouracil, and leucovorin for colorectal eancer[J]. N Engl J Med, 2001, 345(2): 144-145.
4Atsurni R, Suzuki W, Hakusui H. Identification of the metabolites of irinotecan, a new derivative of camptothe- tin, in rat bile and its biliary excretion[J]. Xenobiotica, 1991, 21(9): 1159-1169.
5Takasuna K, Hagiwara T, Hirohashi M, et al. Involve- ment of beta-glucuronidase in intestinal microflora in the intestinal toxicity of the antitumor camptothecin de- rivative irinotecan hydrochloride (CPT-11) in rats[J]. Cancer Res, 1996, 56(16): 3752-3757.
6Schulz C, Boeck S, Heinemann V, et al. UGT1A1 geno- typing: a predictor of irinotecan-associated side effects and drug efficacy? [J] Anticancer Drugs, 2009, 20(10): 867-879.
7Hu ZY, Yu Q, Pei Q, et al. Dose-dependent association between UGT1Al*28 genotype and irinotecan-induced neutropenia: low doses also increase risk[J]. Clin Cancer Res, 2010, 16(15): 3832-3842.
8Ando Y, Saka H, Ando M, et al. Polymorphisms ofUDP-glucuronosyltransferase gene and irinotecan toxici- ty: a pharmacogenetic analysis[J]. Cancer Res, 2000, 60 (24): 6921-6926.
9Guillemette C, Millikan RC, Newman B, et al. Genetic polymorphisms in uridine diphospho-glucuronosyltrans- ferase 1A1 and association with breast cancer among Af- rican Americans[J]. Cancer Res, 2000, 60(4): 950-956.
10Hall D, Ybazeta G, Destro-Bisol G, et al. Variability at the uridine diphosphate glucuronosyltransferase 1A1 promoter in human populations and primates[J]. Phar- macogenetics, 1999, 9(5): 591-599.
